School of Medicine, European University Cyprus, 6 Diogenis Str., 2404 Engomi, P.O. Box 22006, Nicosia 1516, Cyprus.
Int J Mol Sci. 2024 Jan 16;25(2):1110. doi: 10.3390/ijms25021110.
This comprehensive review elucidates the profound relationship between the human microbiome and breast cancer management. Recent findings highlight the significance of microbial alterations in tissue, such as the gut and the breast, and their role in influencing the breast cancer risk, development, progression, and treatment outcomes. We delve into how the gut microbiome can modulate systemic inflammatory responses and estrogen levels, thereby impacting cancer initiation and therapeutic drug efficacy. Furthermore, we explore the unique microbial diversity within breast tissue, indicating potential imbalances brought about by cancer and highlighting specific microbes as promising therapeutic targets. Emphasizing a holistic One Health approach, this review underscores the importance of integrating insights from human, animal, and environmental health to gain a deeper understanding of the complex microbe-cancer interplay. As the field advances, the strategic manipulation of the microbiome and its metabolites presents innovative prospects for the enhancement of cancer diagnostics and therapeutics. However, rigorous clinical trials remain essential to confirm the potential of microbiota-based interventions in breast cancer management.
这篇全面综述阐明了人类微生物组与乳腺癌管理之间的深远关系。最近的研究结果强调了组织中微生物改变的重要性,如肠道和乳房,以及它们在影响乳腺癌风险、发展、进展和治疗结果中的作用。我们深入探讨了肠道微生物组如何调节全身炎症反应和雌激素水平,从而影响癌症的发生和治疗药物的疗效。此外,我们还研究了乳腺组织内独特的微生物多样性,表明癌症带来的潜在失衡,并强调了一些特定的微生物作为有前途的治疗靶点。强调一种整体的“同一健康”方法,这篇综述强调了整合来自人类、动物和环境卫生的见解以更深入了解复杂的微生物-癌症相互作用的重要性。随着该领域的进展,微生物组及其代谢物的策略性操纵为癌症诊断和治疗的增强提供了创新前景。然而,仍需要严格的临床试验来证实基于微生物组的干预措施在乳腺癌管理中的潜力。